Chinmay Jani, Chief Fellow at Sylvester Comprehensive Cancer Center, shared on X:
“Check out our recent analysis The Oncologist under mentorship of Aakash Desai of 653 solid tumors evaluating HER2 by IHC, CNV and mutational profiling.
Results:
- IHC+: 3+ (3.1%), 2+ (13.2%), 1+ (19.8%), 63.9% neg
- CN amplification: 3.1% (75% IHC3+)
- Pathogenic ERBB2 mutations: 3.1% (only 5% IHC3+)
ERBB2-mut tumors rarely show IHC3+/CN amp → highlights need for comprehensive genomic testing.
In the era of pan-tumor T-DXd approval, integrating genomic + phenotypic data can refine patient selection and advance precision oncology.”
Title: HER2 Alterations across Solid Tumors: Implications for Comprehensive Testing
Authors: Ahmed Ismail , Chimay Jani , Nusrat Jahan , Malla Midhun , Arnab Basu , Garima Gupta , Bassel El-Rayes , Sejong Bae , Tyler Mattox , Cyntanna Hawkins , Rebecca C Arend , Mehmet Akce , Yanis Boumber , Aakash Desai
More posts featuring Chinmay Jani.